MLTX
Price
$13.51Alerts
Change
+$0.95 (+7.56%)
Updated
Nov 11 closing price
Capitalization
981.28M
112 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$42.10Alerts
Change
+$0.71 (+1.72%)
Updated
Nov 11 closing price
Capitalization
3.79B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLTX vs XENE

MLTX vs XENE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MLTX vs. XENE commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLTX is a StrongBuy and XENE is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MLTX with price predictions
Nov 11, 2026

MLTX in upward trend: price rose above 50-day moving average on November 09, 2026

MLTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Oscillator exited the oversold zone, 11 of 16 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MLTX as a result. In 83 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.

The 10-day moving average for MLTX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

MLTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MLTX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.498). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for XENE with price predictions
Nov 11, 2026

Momentum Indicator for XENE turns positive, indicating new upward trend

XENE saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 69 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for XENE just turned positive on October 07, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in 30 of 49 cases over the following month. The odds of a continued upward trend are 61%.

XENE moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 189 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for XENE moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

XENE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XENE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.053) is normal, around the industry mean (3.498). P/E Ratio (-8.264) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.930) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XENE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
MLTX vs XENE: Fundamental Ratings
MLTX
XENE
OUTLOOK RATING
1..100
3745
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
9582
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
5860
P/E GROWTH RATING
1..100
1212
SEASONALITY SCORE
1..100
8575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLTX's Valuation (38) in the null industry is somewhat better than the same rating for XENE (76) in the Biotechnology industry. This means that MLTX’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as MLTX (95) in the null industry. This means that XENE’s stock grew similarly to MLTX’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as MLTX (98) in the null industry. This means that XENE’s stock grew similarly to MLTX’s over the last 12 months.

MLTX's Price Growth Rating (58) in the null industry is in the same range as XENE (60) in the Biotechnology industry. This means that MLTX’s stock grew similarly to XENE’s over the last 12 months.

MLTX's P/E Growth Rating (12) in the null industry is in the same range as XENE (12) in the Biotechnology industry. This means that MLTX’s stock grew similarly to XENE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLTXXENE
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 6 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 1 day ago
67%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 29 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
71%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
76%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (MLTX: $12.56 vs. XENE: $41.39)
Brand notoriety: MLTX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLTX: 43% vs. XENE: 109%
Market capitalization -- MLTX: $981.28M vs. XENE: $3.79B
MLTX [@Biotechnology] is valued at $981.28M. XENE’s [@Biotechnology] market capitalization is $3.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLTX’s FA Score shows that 1 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).

  • MLTX’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, MLTX is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLTX’s TA Score shows that 6 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • MLTX’s TA Score: 6 bullish, 3 bearish.
  • XENE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MLTX is a better buy in the short-term than XENE.

Price Growth

MLTX (@Biotechnology) experienced а +7.35% price change this week, while XENE (@Biotechnology) price change was +8.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

MLTX is expected to report earnings on Mar 04, 2027.

XENE is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

MLTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLTX
1D Price
Change %
MLTX100%
+7.56%
KALA - MLTX
82%
Closely correlated
N/A
CGON - MLTX
50%
Loosely correlated
-0.04%
ELVN - MLTX
47%
Loosely correlated
-0.02%
XENE - MLTX
44%
Loosely correlated
+1.72%
BDTX - MLTX
42%
Loosely correlated
+0.94%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+1.72%
RLMD - XENE
49%
Loosely correlated
+3.75%
DNTH - XENE
46%
Loosely correlated
+0.55%
MLTX - XENE
44%
Loosely correlated
+7.56%
DYN - XENE
43%
Loosely correlated
+0.39%
REPL - XENE
42%
Loosely correlated
-6.44%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XOVL17.950.29
+1.63%
Defiance Daily Target 2X Long XOVR ETF (XOVL)
DOCT48.180.34
+0.70%
FT Vest US Equity Deep Buffer ETF - October
DES39.570.20
+0.51%
WisdomTree U.S. SmallCap Dividend Fund (DES)
MAYZ35.57N/A
N/A
TrueShares Structured Outcome (May) ETF (MAYZ)
STXT19.17-0.04
-0.21%
Strive Total Return Bond ETF (STXT)